Anebulo Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Anebulo Pharmaceuticals

07/05/2024 13:41

* Anebulo Pharmaceuticals Inc  ANEB.OQ   ANEB.O  is expected
to show no change in quarterly revenue when it reports 
results on May 9 (estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Anebulo Pharmaceuticals
Inc is
for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anebulo
Pharmaceuticals Inc is $6.00​, above​ its last closing price
of $2.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.10       -0.10      -0.11     Missed  -10
 Sep. 30 2023  -0.12       -0.12      -0.10     Beat    14.3
 Jun. 30 2023  -0.10       -0.11      -0.10     Beat    9.6​
 Mar. 31 2023  -0.16       -0.16      -0.11     Beat    29.9
 ​​Dec.                    -0.11      -0.15     Missed  -36.4
 31 2022                                                
 Sep. 30 2022  -0.11       -0.10      -0.11     Missed  -4.8​
 Jun. 30 2022  -0.08       -0.07      -0.10     Missed  -33.3
 Mar. 31 2022  -0.05       -0.05      -0.08     Missed  -60
 This summary was machine generated May 7 at 12:41 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)